KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to -$30.6 billion.

  • Astrazeneca's Total Current Liabilities fell 987.22% to -$30.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$30.6 billion, marking a year-over-year decrease of 987.22%. This contributed to the annual value of -$30.6 billion for FY2025, which is 987.22% down from last year.
  • Latest data reveals that Astrazeneca reported Total Current Liabilities of -$30.6 billion as of Q4 2025, which was down 987.22% from -$34.1 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Total Current Liabilities high stood at $30.5 billion for Q4 2023, and its period low was -$34.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Total Current Liabilities was -$25.4 billion (2023), whereas its average is -$18.8 billion.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 24505.11% in 2021, then plummeted by 19123.83% in 2024.
  • Astrazeneca's Total Current Liabilities (Quarter) stood at $22.6 billion in 2021, then rose by 16.37% to $26.3 billion in 2022, then grew by 16.16% to $30.5 billion in 2023, then crashed by 191.24% to -$27.9 billion in 2024, then dropped by 9.87% to -$30.6 billion in 2025.
  • Its last three reported values are -$30.6 billion in Q4 2025, -$34.1 billion for Q3 2025, and -$33.5 billion during Q2 2025.